CERS CERUS CORP
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1020214 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY54.2%
TTM EPS YoY50.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1.0%
Net margin-2.9%
FCF margin0.2%
EBITDA margin-0.3%
Returns
ROE-10.7%
ROA-3.5%
ROIC (approx.)-3.8%
Asset turnover1.21x
Leverage & solvency
Liabilities / assets62.7%
Debt / equity0.00x
Current ratio1.96x
Interest coverage-0.36x
Cash quality & payout
Operating cash flow / net income-0.48x
Accruals ratio-5.1%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $233.80M | $201.32M |
| R&D expense | $67.72M | $58.91M |
| SG&A expense | $80.91M | $75.89M |
| Operating income | -$8.68M | -$14.22M |
| Interest expense | $8.34M | $8.88M |
| Pretax income | -$15.28M | -$20.76M |
| Income tax | $354,000 | $205,000 |
| Net income | -$15.63M | -$20.92M |
| EBITDA | -$7.25M | -$12.37M |
| EPS (basic) | -0.08 | -0.11 |
| EPS (diluted) | -0.08 | -0.11 |
| Weighted avg. shares (diluted) | 190.59M | 184.56M |
| Balance sheet | ||
| Cash & equivalents | $19.96M | $21.36M |
| Short-term investments | $62.92M | $60.19M |
| Receivables | $30.37M | $29.78M |
| Inventory | $56.10M | $38.15M |
| Current assets | $174.38M | $152.02M |
| PP&E, net | $9.20M | $7.15M |
| Goodwill | $1.32M | $1.32M |
| Total assets | $221.86M | $200.92M |
| Current liabilities | $100.80M | $63.61M |
| Total liabilities | $156.89M | $144.02M |
| Shareholders' equity | $64.22M | $56.15M |
| Shares outstanding | 192.14M | 185.77M |
| Cash flow statement | ||
| Operating cash flow | $4.84M | $11.36M |
| Capital expenditure | $3.73M | $2.84M |
| Free cash flow | $1.11M | $8.52M |
| Investing cash flow | -$6.17M | -$8.13M |
| Financing cash flow | $231,000 | $4.96M |
| Depreciation & amortization | $1.43M | $1.85M |
| Stock-based compensation | $22.87M | $22.87M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.